UPDATE: Raymond James Downgrades Voyager Therapeutics (VYGR) to Outperform

(updating comment)

Raymond James analyst Reni Benjamin downgraded Voyager Therapeutics (NASDAQ: VYGR) from Strong Buy to Outperform with a price target of $17.00 (from $28.00).

The analyst comments "We our reducing our price target to $17 (versus $28 previously) and an Outperform rating, as consistent delays with both the VY-AADC Parkinson’s program (PD) and Huntington’s (HD) program extends the commercial horizon line. We continue to fundamentally believe that the VY-AADC PD program is better than the indwelling hardware solution now mainly used for advanced PD patients (deep brain stimulation), and the translational data for the HD program has been promising. That said, clearly execution has not been what we had hoped, and timelines for progress continue to face hurdles."

For an analyst ratings summary and ratings history on Voyager Therapeutics click here. For more ratings news on Voyager Therapeutics click here.

Shares of Voyager Therapeutics closed at $11.20 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities